Shanghai Kaibao Pharmaceutical (SHE:300039) — Market Cap & Net Worth
Market Cap & Net Worth: Shanghai Kaibao Pharmaceutical (300039)
Shanghai Kaibao Pharmaceutical (SHE:300039) has a market capitalization of $776.03 Million (CN¥5.30 Billion) as of September 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #10124 globally and #2688 in its home market, demonstrating a -2.87% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shanghai Kaibao Pharmaceutical's stock price CN¥5.07 by its total outstanding shares 1046000000 (1.05 Billion). Also see 300039 total assets for a full breakdown of the balance sheet.
Shanghai Kaibao Pharmaceutical Market Cap History: 2015 to 2026
Shanghai Kaibao Pharmaceutical's market capitalization history from 2015 to 2026. Data shows change from $1.45 Billion to $776.03 Million (-4.75% CAGR). Also see cash flow conversion of Shanghai Kaibao Pharmaceutical for how efficiently the company converts equity into cash flow.
Shanghai Kaibao Pharmaceutical Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shanghai Kaibao Pharmaceutical's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check today's stock price for Shanghai Kaibao Pharmaceutical for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.80x
Shanghai Kaibao Pharmaceutical's market cap is 0.80 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.31x
Shanghai Kaibao Pharmaceutical's market cap is 3.31 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.08 Billion | $1.50 Billion | $282.61 Million | 0.72x | 3.82x |
| 2017 | $884.38 Million | $1.57 Billion | $272.30 Million | 0.56x | 3.25x |
| 2018 | $572.59 Million | $1.50 Billion | $226.81 Million | 0.38x | 2.52x |
| 2019 | $722.55 Million | $1.42 Billion | $250.99 Million | 0.51x | 2.88x |
| 2020 | $716.10 Million | $908.01 Million | $106.12 Million | 0.79x | 6.75x |
| 2021 | $911.72 Million | $1.10 Billion | $140.11 Million | 0.83x | 6.51x |
| 2022 | $1.20 Billion | $1.12 Billion | $190.80 Million | 1.08x | 6.30x |
| 2023 | $1.00 Billion | $1.59 Billion | $327.87 Million | 0.63x | 3.05x |
| 2024 | $945.93 Million | $1.47 Billion | $375.58 Million | 0.64x | 2.52x |
| 2025 | $922.97 Million | $1.15 Billion | $278.58 Million | 0.80x | 3.31x |
Competitor Companies of 300039 by Market Capitalization
Companies near Shanghai Kaibao Pharmaceutical in the global market cap rankings as of September 19, 2026. Review 300039 goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Shanghai Kaibao Pharmaceutical by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #613 globally with a market cap of $44.92 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.99 Billion USD ( CN¥280.10 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #613 | GALDERMA GROUP AG | NYSE:GALDY | $44.92 Billion | $38.53 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.90 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.99 Billion | CN¥43.91 |
Shanghai Kaibao Pharmaceutical Historical Marketcap From 2015 to 2026
Between 2015 and today, Shanghai Kaibao Pharmaceutical's market cap moved from $1.45 Billion to $ 776.03 Million, with a yearly change of -4.75%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥776.03 Million | -15.92% |
| 2025 | CN¥922.97 Million | -2.43% |
| 2024 | CN¥945.93 Million | -5.42% |
| 2023 | CN¥1.00 Billion | -16.86% |
| 2022 | CN¥1.20 Billion | +31.94% |
| 2021 | CN¥911.72 Million | +27.32% |
| 2020 | CN¥716.10 Million | -0.89% |
| 2019 | CN¥722.55 Million | +26.19% |
| 2018 | CN¥572.59 Million | -35.26% |
| 2017 | CN¥884.38 Million | -18.08% |
| 2016 | CN¥1.08 Billion | -25.43% |
| 2015 | CN¥1.45 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Shanghai Kaibao Pharmaceutical was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $776.03 Million USD |
| MoneyControl | $776.03 Million USD |
| MarketWatch | $776.03 Million USD |
| marketcap.company | $776.03 Million USD |
| Reuters | $776.03 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shanghai Kaibao Pharmaceutical
Shanghai Kaibao Pharmaceutical CO.,Ltd engages in the research, development, production, and sale of modern traditional Chinese medicines primarily in China. The company offers heat-clearing and detoxifying products, such as Tanreqing Injection for wind-heat in the lungs with phlegm-heat obstructing the lungs, early-stage pneumonia, acute bronchitis, acute exacerbations of chronic bronchitis, and… Read more